Alecrim Maria G, Lacerda Marcus V, Mourão Maria P, Alecrim Wilson D, Padilha Alexandre, Cardoso Bernardo S, Boulos Marcos
Tropical Medicine Foundation of Amazonas, Manaus, Amazonas, Brazil.
Am J Trop Med Hyg. 2006 Jan;74(1):20-5.
This randomized, open-label study compared a three-day, six-dose regimen of artemether-lumefantrine with a five-day, 19-dose regimen of quinine-doxycycline for the treatment of Plasmodium falciparum malaria in the western Amazon region of Brazil. All patients remained hospitalized during their treatment and the study assessments were scheduled daily from the start of treatment (day 0) through day 6. By day 3, the percentage of infected patients was 0% in the artemether-lumefantrine group and 48.8% in the quinine-doxycycline group. Median parasite clearance time was significantly shorter in the artemether-lumefantrine group (two days) compared with the quinine-doxycycline group (three days) (P < 0.0001). Two patients in the quinine-doxycycline group left the study early because of treatment ineffectiveness or adverse event. Adverse events were reported by 91.5% of the study participants, most of which were mild in severity and/or not considered related to study treatment. Artemether-lumefantrine was shown to be an efficacious, safe, and convenient treatment for P. falciparum malaria in a highly drug-resistant region of South America.
这项随机、开放标签研究比较了蒿甲醚-本芴醇的三日六剂量方案与奎宁-多西环素的五日19剂量方案，用于治疗巴西亚马逊地区西部的恶性疟原虫疟疾。所有患者在治疗期间均住院，研究评估从治疗开始（第0天）至第6天每天进行。到第3天，蒿甲醚-本芴醇组感染患者的百分比为0%，奎宁-多西环素组为48.8%。蒿甲醚-本芴醇组的中位寄生虫清除时间（两天）明显短于奎宁-多西环素组（三天）（P<0.0001）。奎宁-多西环素组有两名患者因治疗无效或不良事件提前退出研究。91.5%的研究参与者报告了不良事件，其中大多数严重程度较轻和/或被认为与研究治疗无关。在南美洲一个高度耐药的地区，蒿甲醚-本芴醇被证明是治疗恶性疟原虫疟疾的一种有效、安全且方便的疗法。
